

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

INSIDE INFORMATION INVESTIGATION AGAINST DIRECTORS AND CONTROLLING SHAREHOLDERS

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rules 13.09(2), 13.51(2) and 13.51B(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has been notified that on May 12, 2026, Mr. Ye Xiaoping (“**Mr. Ye**”), and Ms. Cao Xiaochun (“**Ms. Cao**”), directors and controlling shareholders of the Company, received a case filing notice from the China Securities Regulatory Commission (“**CSRC**”) in relation to suspected violations of laws and regulations regarding information disclosure related to changes in the Company’s shareholding, and the CSRC has decided to initiate an investigation into Mr. Ye and Ms. Cao in accordance with the Securities Law of the People’s Republic of China, the Administrative Penalty Law of the People’s Republic of China and other laws and regulations. Mr. Ye and Ms. Cao will actively cooperate with the CSRC’s relevant work and will fulfill their information disclosure obligations in strict accordance with regulatory requirements.

The Board of Directors of the Company believes that the business operation of the Group remains normal, and that the aforementioned investigation will not affect the Group’s normal operations. Further announcement(s) will be made to keep the shareholders of the Company and the public informed of the development in this matter in due course.

The shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, May 12, 2026

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.